Persistence with medication and overactive bladder: an ongoing challenge [0.03%]
药物治疗与过度活动膀胱：一个持久的挑战
Adrian Wagg
Adrian Wagg
Introduction: For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence t...
Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis [0.03%]
绘制强直性脊柱炎患者的临床和生活质量结果之间关系的图表
Tomas Mlcoch,Liliana Sedova,Jiri Stolfa et al.
Tomas Mlcoch et al.
Aim: To map health-related quality of life (Qol) with clinical parameters BASFI and ASDAS-CRP measure, and other covariates. Methods: O...
Cognitive dysfunction and work productivity in major depressive disorder [0.03%]
抑郁症患者的认知功能障碍与工作能力下降的关系研究
Marci Clark,Dana DiBenedetti,Vanessa Perez
Marci Clark
Introduction: Major depressive disorder (MDD) is strongly associated with poor work-related outcomes. Cognitive dysfunction is prevalent in MDD, and research supports a correlation between greater depression severity and ...
Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis [0.03%]
克罗恩病和溃疡性结肠炎患者的健康效益：系统评价和meta分析
Krzysztof Piotr Malinowski,Paweł Kawalec
Krzysztof Piotr Malinowski
Introduction: The aim of this systematic review was to collect and summarize the current data on the utilities of patients with Crohn's disease (CD) and ulcerative colitis (UC). ...
How peptide technology has improved costs and outcomes in patients with heart failure [0.03%]
肽类技术如何改善心力衰竭患者的成本和预后
Kostas Athanasakis,Ioli Arista,Thanos Balasopoulos et al.
Kostas Athanasakis et al.
Introduction: Heart failure (HF) is characterized by substantial health and economic burden, mainly attributed to increased hospitalizations and readmissions. Its diagnosis remains challenging due to the non-specific natu...
Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective [0.03%]
西班牙医院视角下的重度难治性非焦点致残性痉挛的鞘内巴氯芬治疗的成本效益分析
Joan Vidal,John Slof,David Serrano et al.
Joan Vidal et al.
Background: Current knowledge about long-term economic consequences of Intrathecal Baclofen Therapy (ITB Therapy®) is incomplete. Methods: ...
Is there an alternative to quality-adjusted life years for supporting healthcare decision making? [0.03%]
除了质量调整生命年外，支持医疗决策还有其他选择吗？
Ariel Beresniak,Danielle Dupont
Ariel Beresniak
Introduction: Over the years, a number of criticisms have been raised about the robustness of the Quality-Adjusted Life Years (QALY) indicator and its use in cost-utility analyses; however, costs/QALY are still nowadays r...
Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare [0.03%]
ICER阈值已经过时了吗？在精准医疗时代评估药品的价值
Pricivel Carrera,Maarten J IJzerman
Pricivel Carrera
Adoption of ipilimumab in the United States: a Medicare study [0.03%]
美国Ipilimumab的使用情况——一项关于老年人群的研究
Nengliang Yao,Sekwon Jang
Nengliang Yao